Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Arcellx Inc.
Headquarters: Gaithersburg, MD, United States of America
Website: http://www.arcellx.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Rami Elghandour, MBA
Number Of Employees: 163
Enterprise Value: $3,574,485,274
PE Ratio: -29.41
Exchange/Ticker 1: NASDAQ:ACLX
Exchange/Ticker 2: N/A
Latest Market Cap: $3,430,703,360
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Feb 7, 2024
Management Tracks
Verily names Myoung Cha as chief product officer
Plus: New CFO for Innovent and updates from Takeda, Shionogi, Lexeo, Stuart, Arcellx and more
BioCentury | Nov 16, 2023
Deals
Nov. 15 Quick Takes: Kite, Arcellx expand CAR T deal
Plus: Gilde closes new €740M fund and updates from RefleXion, NMD, Lenz-Graphite, Cytovale, T-Therapeutics, Vittoria, CorMedix
BioCentury | Oct 31, 2023
Management Tracks
CSO, CFO changes at Third Harmonic
Plus: MediLink hires Steve Chin as CMO, and updates from ImmPACT,
BioCentury | Aug 30, 2023
Finance
IPO superstars
Back to School 2023: Six companies with NASDAQ IPOs since 2021 have more than doubled their market caps. Another four met the doubling mark via M&A
BioCentury | Aug 25, 2023
Management Tracks
John Orwin named chairman at Cargo
Plus: Ramzi Benamar joins Elucida as CFO, and updates from Innoviva and Sarfez
BioCentury | Aug 16, 2023
Regulation
Aug. 15 Quick Takes: April PDUFA for Carvykti in earlier stage MM
Plus: Nucleic acid company Impilo launches to treat solid tumors and updates from Galecto, Design, Arcellx, Amicus, Alaunos, Lidao
BioCentury | Jun 21, 2023
Deals
June 20 Quick Takes: FDA approves argenx’s subcutaneous Vyvgart
Plus: Clozel provides Idorsia cash lifeline, a clinical hold for Arcellx and updates from Vera, Denali, Delve Bio and Turbine
BioCentury | Apr 19, 2023
Product Development
Gilead’s next steps in oncology
Ambitious top-10 goal in cancer by 2030, with BD focus on early-stage assets that add mechanisms to pipeline
BioCentury | Apr 5, 2023
Finance
With second post-GSK fund, SR One navigates changes along independent path
Nearly three years after firm’s separation, former parent still a presence, while new hires and sector headwinds drive investment decisions
Items per page:
1 - 10 of 34